1
|
Long-term outcomes of ventral onlay buccal mucosa graft urethroplasty. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00500-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
2
|
POS1130 A RANDOMISED CONTROLLED STUDY OF POLYACRYLAMIDE HYDROGEL VS. HYALURONIC ACID IN KNEE OSTEOARTHRITIS: RESULTS AT 12-MONTHS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundPolyacrylamide hydrogel (iPAAG), manufactured by Contura International, is CE marked for the symptomatic treatment of patients with knee osteoarthritis (OA).iPAAG fulfils an unmet clinical need for an effective, long-acting, safe and minimally invasive treatment that may postpone and potentially prevent knee surgery for those with OA.ObjectivesTo compare the effectiveness of single intra-articular injections of iPAAG and hyaluronic acid (HA) in participants with moderate to severe knee OA.To compare the effectiveness of iPAAG and HA in subgroups based on age, BMI or Kellgren-Lawrence (KL) grade at baseline by assessing changes from baseline in transformed WOMAC pain subscale scores.MethodsThis prospective, double-blind study (NCT04045431) randomized 239 participants to receive a single intra-articular injection of either 6 mL iPAAG (n=119) or 6 mL HA (n=120). The study was approved by the Capital Region’s Committee on Health Research Ethics. All participants provided informed consent prior to study activities.Outcomes included changes in the WOMAC pain, stiffness and function subscales and Patient Global Assessment of disease impact (PGA) at 52 weeks. All statistical analyses were based on the ITT principle using a mixed model for repeated measurement with a restricted maximum likelihood-based approach. The estimated mean treatment difference based on this model was reported with 95 % CI and p-value.ResultsDemographic and baseline characteristics were similar between treatment groups with an average age at treatment of approximately 67 years (range 31 – 90 years) and slightly more females (53%) than males.There was a clinically relevant decrease in WOMAC pain subscale score from baseline to 52 weeks in both groups (Figure 1). There were also clinically relevant decreases in the WOMAC stiffness subscale and physical function subscale and PGA in both groups. Treatment differences in favor of iPAAG compared to HA, were measured for the 3 WOMAC subscales and PGA. However, none of these differences reached statistical significance.Figure 1.Mean plot of transformed WOMAC pain subscale (0-100) – ITT analysis setThe treatment difference in favor of iPAAG compared to HA for the WOMAC pain subscale score was statistically significant in the subgroup with age at baseline <70 years but did not reach statistical significance in the subgroup with age at baseline ≥70 years.The treatment difference in favor of IPAAG compared to HA for the WOMAC pain subscale score was statistically significant in the subgroup with normal BMI but did not reach statistical significance in the subgroups with overweight or obese BMI.The treatment difference in favor of IPAAG compared to HA for the WOMAC pain subscale score was statistically significant in the subgroup with KL grade 2 or 3. In the subgroup with KL grade 4, a treatment difference in favor of HA was not statistically significant.Table 1.Change from baseline in transformed (0-100) WOMAC pain subscale at week 52LSMean (95% CI)Treatment difference (95% CI)p-valueOverall
HA-13.3 (-16.7; -10.0)
iPAAG-17.9 (-21.3; -14.6)4.6 (-0.1; 9.4)0.0572Age <70 years
HA-14.0 (-18.3; -9.6)0.0195
iPAAG-21.3 (-25.5; -17.0)7.3 (1.2; 13.4)Age ≥ 70 years
HA-12.5 (-17.6; -7.4)0.7970
iPAAG-13.4 (-18.7; -8.2)1.0 (-6.3; 8.2)BMI normal
HA-13.5 (-18.1; -8.9)0.0110
iPAAG-17.5 (-22.2; -12.9)10.9 (2.6; 19.1)BMI overweight
HA-14.3 (-19.5; -9.2)0.6114
iPAAG-16.1 (-21.0; -11.3)1.8 (-5.3; 8.9)BMI obese
HA-14.5 (-22.7; -6.2)0.5565
iPAAG-17.8 (-25.6; -10.0)3.3 (-8.0; 14.7)KL grade 2 or 3
HA-13.4 (-17.0; -9.7)0.0332
iPAAG-18.9 (-22.5; -15.4)5.6 (0.5; 10.7)KL grade 4)
HA-13.1 (-21.9; -4.3)0.6757
iPAAG-10.3 (-20.6; 0.0)-2.8 (-16.4; 10.8)ConclusionAt 52 weeks after treatment, the effectiveness of iPAAG was numerically superior to HA but not statistically significantly different.In subgroups of participants with normal BMI, participants <70 years old or participants with KL grade 2 or 3 iPAAG performed statistically significantly better than HA at 52 weeks after treatment.Disclosure of InterestsNone declared
Collapse
|
3
|
The initial validation of a novel outcome measure in severe burns- the Persistent Organ Dysfunction +Death: Results from a multicenter evaluation. Burns 2020; 47:765-775. [PMID: 33288334 DOI: 10.1016/j.burns.2020.09.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2020] [Revised: 08/25/2020] [Accepted: 09/24/2020] [Indexed: 11/19/2022]
Abstract
INTRODUCTION A need exists to improve the efficiency of clinical trials in burn care. The objective of this study was to validate "Persistent Organ Dysfunction" plus death as endpoint in burn patients and to demonstrate its statistical efficiency. METHODS This secondary outcome analysis of a dataset from a prospective international multicenter RCT (RE-ENERGIZE) included patients with burned total body surface area >20% and a 6-month follow-up. Persistent organ dysfunction was defined as persistence of organ dysfunction with life-supportiing technologies and ICU care. RESULTS In the 539 included patients, the prevalence of 0p p+ pdeath was 40% at day 14 and of 27% at day 28. At both timepoints, survivors with POD (vs. survivors without POD) had a higher mortality rate, longer ICU- and hospital-stays, and a reduced quality of life. POD + death as an endpoint could result in reduced sample size requirements for clinical trials. Detecting a 25% relative risk reduction in 28-day mortality would require a sample size of 4492 patients, whereas 1236 patients would be required were 28-day POD + death used. CONCLUSIONS POD + death represents a promising composite outcome measure that may reduce the sample size requirements of clinical trials in severe burns patients. Further validation in larger clinical trials is warranted. STUDY TYPE Prospective cohort study, level of evidence: II.
Collapse
|
4
|
Overall safety and cardiovascular safety of fixed-dose combination of aclidinium/formoterol compared to salmeterol/fluticasone in patients with COPD. Pneumologie 2016. [DOI: 10.1055/s-0036-1572086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
5
|
P126 Efficacy of aclidinium bromide compared with tiotropium and placebo in symptomatic patients with moderate to severe chronic obstructive pulmonary disease (COPD): post-hoc analysis of a Phase IIIb study: Abstract P126 Table 1. Thorax 2015. [DOI: 10.1136/thoraxjnl-2015-207770.263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
6
|
Symptom severity and quality of life in COPD patients treated with aclidinium bromide: results of a non-interventional study. Pneumologie 2015. [DOI: 10.1055/s-0035-1544640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
7
|
Results of three Phase II trials with the long-acting β2-adrenergic agonist (LABA) abediterol in patients with persistent asthma. Pneumologie 2015. [DOI: 10.1055/s-0035-1544687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
8
|
Abediterol (LAS100977), a novel long-acting β2-agonist: efficacy, safety and tolerability in persistent asthma. Respir Med 2014; 108:1424-9. [PMID: 25256258 DOI: 10.1016/j.rmed.2014.08.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/04/2014] [Accepted: 08/15/2014] [Indexed: 10/24/2022]
Abstract
BACKGROUND Abediterol (LAS100977) is a novel, long-acting β2-agonist, in development for the once-daily treatment of asthma in combination with mometasone. Here we report the results of a Phase IIa trial of single doses of abediterol added to ongoing maintenance therapy (inhaled corticosteroids) in patients with persistent mild-to-moderate asthma. METHODS This was a randomised, double-blind, placebo- and active-comparator-controlled, five-way crossover study. Male patients (18-70 years) with a clinical diagnosis of persistent asthma received abediterol (5, 10 and 25 μg), salmeterol and placebo, on top of ongoing maintenance therapy. Lung function was determined using spirometry and whole body plethysmography. The primary efficacy endpoint was change from baseline in trough forced expiratory volume in 1 s (FEV1) after a single dose. RESULTS All three abediterol doses induced statistically significant increases in trough FEV1 vs placebo and salmeterol. Improvements in other lung function parameters were also statistically significantly greater with all abediterol doses vs both placebo (p < 0.0001) and salmeterol (p < 0.05) than the first assessment at 5 min post-dose. These improvements were sustained to 36 h post-dose. The profile of treatment-emergent adverse events judged as related to abediterol was consistent with that seen after adrenergic stimulation and occurred exclusively in patients who received abediterol 10 μg or 25 μg. CONCLUSIONS This first-in-patient study revealed the potent, rapid and long-acting bronchodilatory effect of abediterol in patients with persistent mild-to-moderate asthma together with an overall good safety and tolerability profile. Further studies are now underway to establish the optimal efficacy-safety-tolerability profile for this compound.
Collapse
|
9
|
Die Glow-5 Studie: Wirksamkeit und Sicherheit von Glycopyrronium verglichen mit verblindetem Tiotropium (jeweils einmal täglich) bei Patienten mit COPD. Pneumologie 2014. [DOI: 10.1055/s-0034-1368052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
10
|
AB0273 Efficacy and safety of add-on golimumab treatment in patients with rheumatoid arthritis receiving concomitant methotrexate or leflunomide. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2013-eular.2595] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
11
|
P233 Efficacy and safety of once-daily glycopyrronium compared with blinded tiotropium in patients with COPD: the GLOW5 study. Thorax 2013. [DOI: 10.1136/thoraxjnl-2013-204457.385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
12
|
Inhalator-Präferenz, Bereitschaft zur Weiterbenutzung und kritische Fehler mit den Inhalatoren Genuair® und HandiHaler® bei Patienten mit COPD. Pneumologie 2013. [DOI: 10.1055/s-0033-1334640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
13
|
Effekt von Aclidiniumbromid im Vergleich zu Tiotropium und Placebo auf Bronchodilatation und Symptome bei Patienten mit moderater bis schwerer COPD; eine Phase IIIb Studie. Pneumologie 2013. [DOI: 10.1055/s-0033-1334782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
14
|
P191 QVA149 once daily improves exercise tolerance and lung function in patients with moderate to severe COPD: the BRIGHT study: Abstract P191 Table 1. Thorax 2012. [DOI: 10.1136/thoraxjnl-2012-202678.252] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
15
|
Perioperatives Gerinnungsmanagement in der Mikrochirurgie – Bericht der Konsensus-Workshops im Rahmen der 31. und 32. Jahrestagung der Deutschsprachigen Arbeitsgemeinschaft für Mikrochirurgie der peripheren Nerven und Gefäße (DAM) im November 2009 in Erlangen und November 2010 in Basel. HANDCHIR MIKROCHIR P 2011; 43:376-83. [DOI: 10.1055/s-0031-1291317] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022] Open
|
16
|
VID-07.01 The Intrafascial Nerve Sparing Radical Perineal Prostatectomy. Urology 2011. [DOI: 10.1016/j.urology.2011.07.513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
17
|
MP-12.06 Reconstruction of Extended Urethral Strictures with Buccal Mucosal Graft. Success Rates After 60 Months of Follow-up: Analysis of 184 Patients. Urology 2011. [DOI: 10.1016/j.urology.2011.07.283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
18
|
UP-03.022 Buccal Mucosal Graft in Reconstructive Urology: Uses Beyond Urethral Stricture. Urology 2011. [DOI: 10.1016/j.urology.2011.07.1112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
19
|
Interdisziplinäre Therapie der Ventilatorischen Insuffizienz bei fortgeschrittenem Emphysem, ein Fallbeispiel. Pneumologie 2011. [DOI: 10.1055/s-0031-1272269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
20
|
Eine 3-Perioden, cross-over Studie (Phase II), um den Einflusses des Dosierungszeitpunktes von Aclidinium Bromide auf die Bronchodilatation bei Patienten mit moderater bis schwerer COPD zu beurteilen. Pneumologie 2010. [DOI: 10.1055/s-0030-1251442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
21
|
Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther 2009; 22:492-6. [DOI: 10.1016/j.pupt.2009.05.001] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/02/2008] [Revised: 04/30/2009] [Accepted: 05/07/2009] [Indexed: 11/16/2022]
|
22
|
Indacaterol –Überblick über das kardiale Sicherheitsprofil bei COPD. Pneumologie 2009. [DOI: 10.1055/s-0029-1214138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
23
|
Vergleich der bronchodilatatorischen Wirksamkeit von Indacaterol und Formoterol bei COPD-Patienten auf FEV1 und Inspiratorische Kapazität. Pneumologie 2009. [DOI: 10.1055/s-0029-1214137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
24
|
Interventionelle Therapie bei beidseitiger idiopathischer Zwerchfellparese ein Fallbeispiel. Pneumologie 2009. [DOI: 10.1055/s-0029-1213975] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
25
|
Antiinflammatory properties of ambroxol. Eur J Med Res 2008; 13:557-562. [PMID: 19073395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023] Open
Abstract
Ambroxol is frequently used as mucolytic agent in respiratory diseases associated with increased mucus production like acute or chronic bronchitis. Further, ambroxol is used topically (lozenges) for the treatment of sore throat and pharyngitis associated with common cold. In addition to the effects of ambroxol on mucus regulation and local anaesthetic effects, a wide range of pharmacological antiinflammatory properties of ambroxol have been described in vitro and in vivo, including inhibition or scavenging of oxidative and nitro?sative stress, increase of local defense molecules involved in respiratory virus replication, reduction of proinflammatory cytokines and arachidonic acid meta?bolites, inflammatory cell chemotaxis, and lipid peroxidation of tissues. The present review summarizes the antiinflammatory effects of ambroxol and relates these properties to results from controlled clinical trials in targeted diseases such as chronic bronchitis, chronic obstructive pulmonary disease and sore throat.
Collapse
|
26
|
Efficacy of tiotropium bromide (Spiriva®) in patients with chronic obstructive pulmonary disease (COPD) of different severities. Pneumologie 2008. [DOI: 10.1055/s-2008-1038143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
27
|
24-stündige Wirksamkeit von Indacaterol nach einmal täglicher Gabe bei moderater bis schwerer COPD. Pneumologie 2008. [DOI: 10.1055/s-2008-1074119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
28
|
Sicherheit von Indacaterol nach einmal täglicher Gabe bei moderater bis schwerer COPD. Pneumologie 2008. [DOI: 10.1055/s-2008-1074116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
29
|
Comment on: Microsurgical arterovenous loops and biological templates: a novel in vivo chamber for tissue engineering. Microsurgery 2008; 28:210-1. [PMID: 18286650 DOI: 10.1002/micr.20467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
30
|
Handle with care: targeting neutrophils in chronic obstructive pulmonary disease and severe asthma? Clin Exp Allergy 2006; 36:142-57. [PMID: 16433851 DOI: 10.1111/j.1365-2222.2006.02418.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Neutrophils play an important role in the pathogenesis of airway inflammation in both chronic obstructive pulmonary disease (COPD) and severe asthma. Currently available drugs have only limited effects on neutrophilic airway inflammation, particularily in COPD. Therefore, great efforts are undertaken to address neutrophilic inflammation in chronic respiratory disorders, in particular COPD. This review summarizes the rationale for anti-neutrophilic treatment in COPD and asthma and gives a critical overview of current developments in drug therapy. Moreover, unanswered questions and limitations of clinical trial design and choice of outcome parameters for proof-of-concept studies with novel anti-neutrophilic drugs are discussed as well as potential safety issues.
Collapse
|
31
|
Gibt es eine Indikation für das Pro-ACT – System bei der Stressinkontinenz-Therapie des Mannes? Aktuelle Urol 2006. [DOI: 10.1055/s-2006-947585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
32
|
Die radikale perineale Prostatektomie (RPP) – perioperative Morbidität, Onkologie und funktionelle Ergebnisse. Eine prospektive Studie an 380 konsekutiven Patienten. Aktuelle Urol 2006. [DOI: 10.1055/s-2006-947445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
33
|
Komplexe rekonstruktive Eingriffe an der Harnröhre: Komplikationen und deren Vermeidung. Aktuelle Urol 2006. [DOI: 10.1055/s-2006-947561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
34
|
Hypospadiekorrektur durch Tubularisierung der Urethralplatte – Ergebnisse bei 140 penilen und distal-penilen primären Hypospadiekorrekturen und 19 Redo-Operation mittels tubularisierter inzidierter Urethralplatte und Tubularisierung ohne Inzision. Aktuelle Urol 2006. [DOI: 10.1055/s-2006-947462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
35
|
Einfluss der Lymphknotendissektion auf die Morbidität und funktionellen Ergebnisse der radikalen perinealen Prostatektomie (RPP). Aktuelle Urol 2006. [DOI: 10.1055/s-2006-947446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
36
|
Rezidiv-Striktur nach Harnröhrenrekonstruktion mit freiem Mundschleimhauttransplantat: Was nun? Aktuelle Urol 2006. [DOI: 10.1055/s-2006-947581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
37
|
Wirksamkeit von Tiotropiumbromid (Spiriva®) bei verschiedenen Schweregraden der chronisch-obstruktiven Lungenerkrankung (COPD). Pneumologie 2006; 60:341-6. [PMID: 16761228 DOI: 10.1055/s-2005-919145] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
BACKGROUND Aim of this study was to evaluate the efficacy of inhaled Tiotropium bromide in COPD patients of different severities in pneumological practices during a three months clinical trial. METHODS A randomized, double blind, placebo controlled study including COPD-patients (FEV1/FVC < 70 %, FEV1 < or = 70 % predicted; age > or = 40 years; > or = 10 pack years) of different severities was performed. The efficacy of 18 microg Tiotropium bromide once daily on lung function and exacerbations over 12 weeks was evaluated by respective pulmonary function tests (spirometry) before (trough value) and 2 hours after inhalation of study medication. RESULTS 1639 patients (1236 Tiotropium bromide, 403 placebo; FEV1 reversibility after 200 microg Ipratropium bromide + 200 microg Fenoterol: 7.9 +/- 7.5 % predicted [mean +/- sd]) were randomized. After 12 weeks of treatment Tiotropium bromide led to significant increases of trough FEV1 (23 - 24 h after last inhalation; + 79 +/- 17 ml), and 2 h after Tiotropium bromide inhalation (+ 128 +/- 19 ml) (all values vs. placebo, adjusted mean +/- se, p < 0.0001). FVC and IVC were also improved significantly. In mild COPD (FEV1 > or = 50 - 70 %) improvements were most pronounced (trough FEV1 + 113 +/- 29 ml, 2 h post-inhalation + 181 +/- 33 ml; all values vs. placebo., p < 0.0001). 14.6 % of patients treated with Tiotropium bromide had a COPD exacerbation vs. 19.9 % of patients treated with placebo (p = 0.0151). The time to first exacerbation was prolonged (p = 0.0092 vs. placebo). CONCLUSION Tiotropium bromide 18 microg once daily led to a persistent improvement of lung function and a reduction of exacerbations in patients with COPD of different severities.
Collapse
|
38
|
Diagnose weisende und meist belastende Symptome bei Patienten mit COPD. Pneumologie 2006. [DOI: 10.1055/s-2006-933747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
39
|
|
40
|
Differentiation of embryonic stem cells into type-II pneumocytes. Pneumologie 2006. [DOI: 10.1055/s-2005-925492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
41
|
[Novel perspectives of COPD pharmacotherapy: focus on neutrophils]. Pneumologie 2005; 59:770-82. [PMID: 16385438 DOI: 10.1055/s-2005-915562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Inflammation in COPD is characterized by an increased presence and activation of airway neutrophils. However, since currently available treatment options have only limited effects on neutrophilic airway inflammation, great efforts are undertaken to develop novel therapies targeting the neutrophilic component of inflammation in COPD. The present review discusses the rationale for anti-neutrophilic treatment in COPD and provides a critical overview of recent developments in drug therapy. Moreover, open questions and limitations of clinical trials including choice of adequate outcome parameters for proof-of-concept studies with putative anti-neutrophilic drugs and potential safety issues are summarized.
Collapse
|
42
|
Abstract
Skin replacement has been a challenging task for surgeons ever since the introduction of skin grafts by Reverdin in 1871. Recently, skin grafting has evolved from the initial autograft and allograft preparations to biosynthetic and tissue-engineered living skin replacements. This has been fostered by the dramatically improved survival rates of major burns where the availability of autologous normal skin for grafting has become one of the limiting factors. The ideal properties of a temporary and a permanent skin substitute have been well defined. Tissue-engineered skin replacements: cultured autologous keratinocyte grafts, cultured allogeneic keratinocyte grafts, autologous/allogeneic composites, acellular biological matrices, and cellular matrices including such biological substances as fibrin sealant and various types of collagen, hyaluronic acid etc. have opened new horizons to deal with such massive skin loss. In extensive burns it has been shown that skin substitution with cultured grafts can be a life-saving measure where few alternatives exist. Future research will aim to create skin substitutes with cultured epidermis that under appropriate circumstances may provide a wound cover that could be just as durable and esthetically acceptable as conventional split-thickness skin grafts. Genetic manipulation may in addition enhance the performance of such cultured skin substitutes. If cell science, molecular biology, genetic engineering, material science and clinical expertise join their efforts to develop optimized cell culture techniques and synthetic or biological matrices then further technical advances might well lead to the production of almost skin like new tissue-engineered human skin products resembling natural human skin.
Collapse
|
43
|
Kinetik des nasalen und exhalierten Stickstoffmonoxids (NO) bei allergischer Früh- und Spätreaktion: Gemeinsamkeiten und Unterschiede. Pneumologie 2005. [DOI: 10.1055/s-2005-864319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
44
|
Saisonale Schwankungen des Serum-IgE-Spiegels und deren mögliche Bedeutung für die Berechnung der therapeutischen Dosis von Omalizumab (rhuMab-E25, anti-IgE). Pneumologie 2004; 58:546-51. [PMID: 15293167 DOI: 10.1055/s-2004-818483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
BACKGROUND The anti-IgE antibody Omalizumab has been approved for the treatment of perennial allergic asthma. Dosing of omalizumab is adjusted according to total IgE levels and body weight, and a near complete suppression of free IgE is deemed to be necessary for optimal efficacy. Many asthmatics, however, have additional sensitisations against seasonal allergens, e. g. pollen, and seasonal exposure may increase total and specific IgE levels ("boost"), thus leading to an imbalance between IgE levels and omalizumab with possible impact on therapeutic outcome. METHODS We studied serum total and specific (timothy grass) IgE levels in 17 patients with seasonal allergic rhinitis and/or asthma prior to and during the grass pollen season. Based on total IgE levels, we then calculated hypothetical doses of omalizumab required for treatment at each time point. RESULTS During the pollen season, total IgE increased significantly from a pre-seasonal mean of 89 (50 - 178) kU/l (geom. mean with 95 % confidence interval) to 126 (63 - 251) kU/l (p = 0.0006). Accordingly, specific IgE increased from 11 (6.3 - 19) kU/l to 15.1 (8.3 - 29) kU/l (p = 0.0013). Calculated doses of omalizumab based on pre-seasonal IgE levels were: no dosing (IgE < 30 kU/l): n = 2; 150 mg 4-weekly: n = 7; 300 mg 4-weekly: n = 2; 225 mg 2-weekly: n = 4; 300 mg 2-weekly: n = 1; 375 mg 2-weekly: n = 1. Based on seasonal IgE levels, doses of omalizumab would have changed in 5/17 patients requiring the next possible dosing step. Of these, two patients would have fallen out of the current dosing scheme. CONCLUSIONS A seasonal increase of serum total and specific IgE can be observed in patients with pollen allergy, although this increase would have no impact on omalizumab doses in the majority of patient. Individual variations, however, can be large and necessitate a dose correction. Therefore, therapeutic monitoring of free IgE levels during anti-IgE treatment appears as desirable tool.
Collapse
|
45
|
Stability of glutathione in induced sputum: impact of freezing. Respiration 2004; 70:523-7. [PMID: 14665779 DOI: 10.1159/000074211] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2002] [Accepted: 05/15/2003] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Oxidative stress has repeatedly been linked to the pathogenesis of pulmonary disorders like asthma and chronic obstructive pulmonary disease. Measuring glutathione (GSH) in induced sputum (IS) offers a noninvasive tool to study oxidative stress in airway diseases. OBJECTIVES This study assessed the stability of GSH in sputum supernatant under varying conditions. METHODS GSH in IS of 14 (7 healthy, 4 chronic obstructive pulmonary disease, 3 allergic rhinitis) nonsmoking subjects was quantified spectrophotometrically. The stability of GSH in supernatant was analyzed over 24 h under different ambient conditions (room temperature and cooling at 4 degrees C). Reproducibility of GSH measurements in immediately processed and frozen supernatant (+72 h) was expressed by intraclass correlation coefficient (R(i)) and coefficient of repeatability (CR). RESULTS GSH recovery in supernatant decreased in a time- and temperature-dependent manner. Samples stored at 4 degrees C and room temperature showed a rapid decline of stability after 2 h. Mean GSH concentrations in IS after freezing (-20 degrees C) and thawing after 72 h were not significantly different from GSH values measured immediately after processing of the samples (immediate processing: 17.9 +/- 13.9 microM; 72 h freezing: 16.4 +/- 12.9 microM, p = 0.2). The reproducibility between immediately processed and frozen samples was excellent (R(i) = 0.97; CR = 5.7 microM). CONCLUSIONS Storage of sputum supernatant at room temperature or 4 degrees C leads to a rapid decline of GSH recovery compared with baseline values. Immediate freezing of samples is a suitable and valid alternative to rapid processing and allows collection and shipment of samples for subsequent analysis.
Collapse
|
46
|
Der Phosphodiesterase-IV-Inhibitor Piklamilast inhibiert die Sauerstoffradikalenfreisetzung aus Sputumzellen und Blutneutrophilen von Patienten mit COPD. Pneumologie 2004. [DOI: 10.1055/s-2004-819574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
47
|
Erhöhte Konzentrationen von Glutathion im induzierten Sputum von Patienten mit mildem oder mittelschwerem Asthma bronchiale: Einfluss der Therapie. Pneumologie 2004. [DOI: 10.1055/s-2004-819566] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
48
|
Wirksamkeit von Tiotropium (Spiriva®) bei Patienten mit COPD nach Umstellung einer Vorbehandlung mit kurzwirksamen Anticholinergika. Pneumologie 2004. [DOI: 10.1055/s-2004-819653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
49
|
Oxidiertes Glutathion und Nitrosothiole sind im induzierten Sputum von Patienten mit COPD erhöht. Pneumologie 2004. [DOI: 10.1055/s-2004-819573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
50
|
Wirksamkeit von Tiotropium (Spiriva®) bei verschiedenen Schweregraden der COPD. Pneumologie 2004. [DOI: 10.1055/s-2004-819652] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|